
| 2019 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Total Project Funding per Partner: | > 1000 |
| Total Number of Projects: | > 1000 |
| 2016 | |
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
| 2012 | |
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
| Networking Rank (Reputation): | > 1000 |
| 2011 | |
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
Total number of projects: 7
As coordinator: 0
As participant: 7
Sole participant: 0
Coordinator / Participant Ratio: 0*
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2022 | 0 | 2.650.313 | 260.539 | 1 | ||
| 2019 | 0 | 3.508.622 | 505.577 | 1 | ||
| 2016 | 0 | 8.684.869 | 623.041 | 3 | ||
| 2012 | 0 | 2.008.622 | 779.339 | 1 | ||
| 2011 | 0 | 5.999.998 | 1.099.860 | 1 | ||
Total number of partners: 77
Partner loyalty:
Frequent Partner: (> 2 projects): 3
Rare Partner: 74
Frequent / Rare Partner Ratio: 0.04
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2022-10-01 | DNA replication at the heart of cell fate decisions and cancer development | RepliFate | participant | 2.650.313 | 21 |
| 2019-10-01 | DNA helicases in genome maintenance: from molecular and cellular mechanisms to specific inhibitors as potential drugs | AntiHelix | participant | 3.508.622 | 9 |
| 2016-04-01 | A multidisciplinary approach to cell division: From human oocyte to synthetic biology | DivIDe | participant | 2.802.399 | 9 |
| 2016-02-01 | Targeted small-molecule Stabilisation of Protein-Protein Interactions | TASPPI | participant | 3.342.323 | 12 |
| 2016-01-01 | Big Data in Chemistry | BIGCHEM | participant | 2.540.146 | 17 |
| 2012-01-01 | Small molecule stabilizers of 14-3-3 Protein-Protein Interactions as novel drugs in cancer and neurodegenerative diseases | 14-3-3Stabs | participant | 2.008.622 | 5 |
| 2011-06-01 | Innovative anti-influenza drugs excluding viral escape | ANTIFLU | participant | 5.999.998 | 11 |